I don't think it is justified. OnCore drugs are all preclinical, not even p1. Lots of stuff sound good on paper or in test tube, but HBV is a tough nut to crack. I wait it out until there is some evidence that this combo approach is working, there is plenty of time.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.